It's Unlikely That The CEO Of iBio, Inc. (NASDAQ:IBIO) Will See A Huge Pay Rise This Year

Key Insights

• iBio to hold its Annual General Meeting on 20th of November
• Salary of US$539.4k is part of CEO Martin Brenner's total remuneration
• The total compensation is similar to the average for the industry
• iBio's EPS grew by 96% over the past three years while total shareholder loss over the past three years was 96%

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Shareholders of iBio, Inc. (NASDAQ:IBIO) will have been dismayed by the negative share price return over the last three years. However, what is unusual is that EPS growth has been positive, suggesting that the share price has diverged from fundamentals. Shareholders may want to question the board on the future direction of the company at the upcoming AGM on 20th of November. They could also try to influence management and firm direction through voting on resolutions such as executive remuneration and other company matters. We think shareholders might be reluctant to increase compensation for the CEO at the moment, according to our analysis below.

View our latest analysis for iBio

How Does Total Compensation For Martin Brenner Compare With Other Companies In The Industry?

At the time of writing, our data shows that iBio, Inc. has a market capitalization of US$25m, and reported total annual CEO compensation of US$1.5m for the year to June 2025. We note that's an increase of 19% above last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$539k.

In comparison with other companies in the American Biotechs industry with market capitalizations under US$200m, the reported median total CEO compensation was US$1.3m. So it looks like iBio compensates Martin Brenner in line with the median for the industry.

On an industry level, roughly 20% of total compensation represents salary and 80% is other remuneration. According to our research, iBio has allocated a higher percentage of pay to salary in comparison to the wider industry. It's important to note that a slant towards non-salary compensation suggests that total pay is tied to the company's performance.

iBio, Inc.'s Growth

iBio, Inc.'s earnings per share (EPS) grew 96% per year over the last three years. Its revenue is up 78% over the last year.

Shareholders would be glad to know that the company has improved itself over the last few years. It's great to see that revenue growth is strong, too. These metrics suggest the business is growing strongly. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings..

Has iBio, Inc. Been A Good Investment?

With a total shareholder return of -96% over three years, iBio, Inc. shareholders would by and large be disappointed. Therefore, it might be upsetting for shareholders if the CEO were paid generously.

To Conclude...

Shareholders have not seen their shares grow in value, rather they have seen their shares decline. A huge lag in share price growth when earnings have grown may indicate there could be other issues that are affecting the company at the moment that the market is focused on. Shareholders would be keen to know what's holding the stock back when earnings have grown. At the upcoming AGM, shareholders will get the opportunity to discuss any issues with the board, including those related to CEO remuneration and assess if the board's plan will likely improve performance in the future.

CEO compensation is an important area to keep your eyes on, but we've also need to pay attention to other attributes of the company. We did our research and identified 4 warning signs (and 2 which are potentially serious) in iBio we think you should know about.

Important note: iBio is an exciting stock, but we understand investors may be looking for an unencumbered balance sheet and blockbuster returns. You might find something better in this list of interesting companies with high ROE and low debt.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.